PHARMACYTE BIOTECH, INC. Increase (Decrease) in Other Accrued Liabilities
PHARMACYTE BIOTECH, INC. (PMCB) reported Increase (Decrease) in Other Accrued Liabilities of -$177.18 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accrued liabilities for the quarter ending 2026-07-31 was -$177.18K.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accrued liabilities for the quarter ending 2026-04-30 was $77.17K, a 94.33% decline year-over-year.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accrued liabilities for the quarter ending 2026-01-31 was -$544.00K, a 54400100.00% decline year-over-year.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accrued liabilities for the quarter ending 2025-10-31 was -$75.00K, a 932.13% decline year-over-year.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accrued liabilities for fiscal 2026 was -$1.55M, a 218.15% decline from fiscal 2025.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accrued liabilities for fiscal 2025 was $1.31M, a 589.99% increase from fiscal 2024.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accrued liabilities for fiscal 2024 was $189.92K.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accrued liabilities for fiscal 2023 was -$40.71K.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$177.18K 10-Q · filed 2026-09-14 | -$100.00K derived: sum of 2 quarters · filed 2026-09-14 | -$644.00K derived: sum of 3 quarters · filed 2026-09-14 | -$719.00K derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $77.17K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | -$466.82K derived: sum of 2 quarters · filed 2026-07-29 | -$541.83K derived: sum of 3 quarters · filed 2026-07-29 | -$1.55M 10-K · filed 2026-07-29 |
| 2026-01-31 | -$544.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | -$619.00K derived: sum of 2 quarters · filed 2026-03-17 | -$1.63M 10-Q · filed 2026-03-17 | -$265.50K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | -$75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-18 | -$1.08M 10-Q · filed 2025-12-18 | $278.50K derived: sum of 3 quarters · filed 2026-09-14 | $278.50K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | -$1.01M 10-Q · filed 2026-09-14 | $353.50K derived: sum of 2 quarters · filed 2026-09-14 | $353.50K derived: sum of 3 quarters · filed 2026-09-14 | $362.52K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $1.36M derived: sum of 2 quarters · filed 2026-07-29 | $1.37M derived: sum of 3 quarters · filed 2026-07-29 | $1.31M 10-K · filed 2026-07-29 |
| 2025-01-31 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | $9.01K derived: sum of 2 quarters · filed 2026-03-17 | -$49.47K 10-Q · filed 2026-03-17 | $94.54K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-10-31 | $9.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-18 | -$49.47K 10-Q · filed 2025-12-18 | $94.54K derived: sum of 3 quarters · filed 2025-12-18 | -$153.18K derived: sum of 4 quarters · filed 2025-12-18 |
| 2024-07-31 | -$58.48K 10-Q · filed 2025-09-15 | $85.53K derived: sum of 2 quarters · filed 2025-09-15 | -$162.19K derived: sum of 3 quarters · filed 2025-09-15 | $109.70K derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | $144.01K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-11 | -$103.71K derived: sum of 2 quarters · filed 2025-08-11 | $168.19K derived: sum of 3 quarters · filed 2025-08-11 | $189.92K 10-K · filed 2025-08-11 |
| 2024-01-31 | -$247.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-17 | $24.17K derived: sum of 2 quarters · filed 2025-03-17 | $45.91K 10-Q · filed 2025-03-17 | |
| 2023-10-31 | $271.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-13 | $293.63K 10-Q · filed 2024-12-13 | ||
| 2023-07-31 | $21.74K 10-Q · filed 2024-09-17 | |||
| 2023-04-30 | -$40.71K 10-K · filed 2024-08-13 | |||
| 2015-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-03-13 | -$36.61K derived: sum of 2 quarters · filed 2015-03-13 | -$33.96K 10-Q · filed 2015-03-13 | -$30.72K derived: sum of 4 quarters · filed 2015-03-13 |
| 2014-10-31 | -$36.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-15 | -$33.96K 10-Q · filed 2014-12-15 | -$30.72K derived: sum of 3 quarters · filed 2014-12-15 | -$27.69K derived: sum of 4 quarters · filed 2015-03-13 |
| 2014-07-31 | $2.65K 10-Q · filed 2014-09-15 | $5.89K derived: sum of 2 quarters · filed 2014-09-15 | $8.92K derived: sum of 3 quarters · filed 2015-03-13 | $10.76K derived: sum of 4 quarters · filed 2015-03-13 |
| 2014-04-30 | $3.24K derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-04 | $6.27K derived: sum of 2 quarters · filed 2015-03-13 | $8.11K derived: sum of 3 quarters · filed 2015-03-13 | $16.01K 10-K · filed 2014-08-04 |
| 2014-01-31 | $3.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-03-13 | $4.87K derived: sum of 2 quarters · filed 2015-03-13 | $12.77K 10-Q · filed 2015-03-13 | $24.04K derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-10-31 | $1.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-12-15 | $9.74K 10-Q · filed 2014-12-15 | $21.01K derived: sum of 3 quarters · filed 2014-12-15 | $31.78K derived: sum of 4 quarters · filed 2014-12-15 |
| 2013-07-31 | $7.90K 10-Q · filed 2014-09-15 | $19.17K derived: sum of 2 quarters · filed 2014-09-15 | $29.94K derived: sum of 3 quarters · filed 2014-09-15 | |
| 2013-04-30 | $11.27K derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-04 | $22.04K derived: sum of 2 quarters · filed 2014-08-04 | $40.80K 10-K · filed 2014-08-04 | |
| 2013-01-31 | $10.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-03-17 | $29.53K 10-Q · filed 2014-03-17 | ||
| 2012-10-31 | $18.76K 10-Q · filed 2013-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |